Compare Summit Therapeutics Inc (SMMT) vs XPO Inc. Common Stock (XPO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs XPO Inc. Common Stock — how do they compare? Summit Therapeutics Inc trades at $17.59 (market cap $13.71B), while XPO Inc. Common Stock trades at $183.47 (market cap $21.30B). The key difference: XPO Inc. Common Stock is the larger of the two by market cap, and XPO Inc. Common Stock is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and XPO Inc. Common Stock for 1 Days on average.
| SMMT | XPO | |
|---|---|---|
Market Cap | $13.71B | $21.30B |
Volume | 6,173,057 | 897,705 |
Sector | Health | Industrials |
52-Week High | $26.38 | $228.37 |
52-Week Low | $12.43 | $123.66 |
Typical Hold Time | 16 Days | 1 Days |
Enterprise Value | $13.04B | $24.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported no revenue in 2025 and a net loss of $1.08 billion, but recent news of a $2 billion strategic investment from AstraZeneca and clinical collaborations has driven significant positive sentiment. Analyst consensus is strongly bullish with a $29.33 price target, reflecting optimism around its cancer drug pipeline.
The outlook hinges on successful clinical trials for ivonescimab, with potential upside from partnership milestones. Key risks include high cash burn, reliance on pipeline success, and competitive pressures. Investors should weigh the speculative nature of biotech investing against the substantial institutional backing and analyst confidence.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About XPO Inc. Common Stock
XPO provides freight transportation services in North America and Europe. Its operations include less-than-truckload freight transportation and brokerage services supported by a technology platform.
Read more on XPO →
